VEA
PCVX icon

Virtus ETF Advisers’s Vaxcyte PCVX Stock Holding History

Virtus ETF Advisers’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,500
Closed -$203K – 557
2026
Q1 		$203K Hold
3,500
– – 0.09% 236
2025
Q4 		$161K Buy
+3,500
New +$157K 0.08% 280
2025
Q1 		– Sell
-809
Closed -$66.2K – 686
2024
Q4 		$66.2K Sell
809
-435
-35% -$43.2K 0.03% 410
2024
Q3 		$142K Buy
1,244
+21
+2% +$1.89K 0.07% 331
2024
Q2 		$92.3K Sell
1,223
-209
-15% -$14.2K 0.05% 349
2024
Q1 		$97.8K Sell
1,432
-96
-6% -$6.65K 0.05% 369
2023
Q4 		$96K Sell
1,528
-355
-19% -$18.4K 0.06% 376
2023
Q3 		$96K Sell
1,883
-192
-9% -$9.47K 0.06% 337
2023
Q2 		$104K Sell
2,075
-136
-6% -$6.45K 0.06% 364
2023
Q1 		$82.9K Sell
2,211
-853
-28% -$36.2K 0.05% 381
2022
Q4 		$147K Sell
3,064
-2,846
-48% -$112K 0.08% 351
2022
Q3 		$142K Buy
5,910
+45
+0.8% +$1.14K 0.06% 362
2022
Q2 		$128K Buy
+5,865
New +$136K 0.05% 358

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Virtus ETF Advisers's PCVX Position: Q2 2026 in Review

Virtus ETF Advisers sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 3,500 shares — an estimated $203K sold.

Virtus ETF Advisers first reported a position in PCVX in Q2 2022 and held it in 13 quarters. The position peaked at $203K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Virtus ETF Advisers reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,500 Vaxcyte shares in Q2 2026, an estimated $203K.
  • Virtus ETF Advisers first reported a position in Vaxcyte in Q2 2022 and held it in 13 quarters.
  • Virtus ETF Advisers's Vaxcyte position peaked at $203K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.